Arax Capital Partners appeared to be the VC, which was created in 2007. The main department of described VC is located in the Vienna. The venture was found in Europe in Austria.
The fund was created by Christian Tiringer, Daniel Cesky. The overall number of key employees were 1.
Deals in the range of 1 - 5 millions dollars are the general things for fund. The higher amount of exits for fund were in 2015. When the investment is from Arax Capital Partners the average startup value is 10-50 millions dollars. The top activity for fund was in 2013. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year. Opposing the other organizations, this Arax Capital Partners works on 24 percentage points less the average amount of lead investments. The real fund results show that this VC is 15 percentage points less often commits exit comparing to other companies.
For fund there is a match between the location of its establishment and the land of its numerous investments - Austria. Among the most successful fund investment fields, there are Information Technology, Semiconductor. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Nabriva Therapeutics, AFFiRiS, EUCODIS Bioscience. The fund has exact preference in a number of founders of portfolio startups.
The standard case for the fund is to invest in rounds with 1-2 partakers. Despite the Arax Capital Partners, startups are often financed by MIG AG, bmp Ventures, RFID Invest. The meaningful sponsors for the fund in investment in the same round are MIG AG, aws Gru00fcnderfonds (aws Founders Fund), Wiener Wachstumsfonds. In the next rounds fund is usually obtained by MIG AG, bmp Ventures, aws Mittelstandsfonds.
Related Funds
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Greenpass | 24 Sep 2024 | - | |||
Calyxha Biotechnologies GmbH | $1M | 28 Feb 2020 | - | ||
EveliQure Biotechnologies GmbH | $2M | 01 Jul 2019 | Vienna, Austria | ||
The MoonVision | $708K | 31 Jan 2019 | Vienna, Austria | ||
Panoptes Pharma | 02 Nov 2015 | Vienna, Austria | |||
crystalsol | $9M | 30 Jan 2013 | Austria, Vienna | ||
Marinomed | $182K | 30 Jun 2012 | Austria, Vienna | ||
crystalsol | $944K | 31 Dec 2011 | Vienna, Austria | ||
EUCODIS Bioscience | $2M | 17 Mar 2010 | Austria, Vienna |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Greenpass | 24 Sep 2024 | - | |||
Calyxha Biotechnologies GmbH | $1M | 28 Feb 2020 | - | ||
EveliQure Biotechnologies GmbH | $2M | 01 Jul 2019 | Vienna, Austria | ||
The MoonVision | $708K | 31 Jan 2019 | Vienna, Austria | ||
Panoptes Pharma | 02 Nov 2015 | Vienna, Austria | |||
crystalsol | $9M | 30 Jan 2013 | Austria, Vienna | ||
Marinomed | $182K | 30 Jun 2012 | Austria, Vienna | ||
crystalsol | $944K | 31 Dec 2011 | Vienna, Austria | ||
EUCODIS Bioscience | $2M | 17 Mar 2010 | Austria, Vienna |